Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 18/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.55 |
| ▸ | PDE4A | P27815 | 12/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 11/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 11/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1758630 | 0.86 | PDE10A (0.46) | PDE10APDE4BPDE4APDE3BPDE3A | |
| SCHEMBL24951298 | 0.85 | PDE10A (0.64) | PDE10APDE4BPDE4APDE3BPDE3A | |
| SCHEMBL187400 | 0.83 | PDE10A (0.66) | PDE10APDE4BPDE4APDE3BPDE3A | |
| SCHEMBL1758454 | 0.82 | PDE10A (0.55) | PDE10APDE4BPDE4APDE3BPDE3A | |
| SCHEMBL4777045 | 0.78 | PDE4B (0.45) | PDE10APDE4BPDE4APDE3BPDE3A | |
| SCHEMBL187041 | 0.78 | PDE10A (0.64) | PDE10APDE4BPDE4APDE3BPDE3A | |
| SCHEMBL1759050 | 0.77 | PDE10A (0.51) | PDE10APDE4BPDE4APDE3BPDE3A | |
| SCHEMBL1758443 | 0.76 | PDE10A (0.70) | PDE10A | |
| SCHEMBL1957932 | 0.75 | F2 (0.62) | — | |
| SCHEMBL188012 | 0.74 | PDE10A (0.63) | PDE10APDE4BPDE4APDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8852554-B2 | Radiolabelled PDE10 ligands | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| EP-2493513-B1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-30 | — | — | EP | disclosed |
| EP-2493513-A1 | RADIOLABELLED PDE10 LIGANDS | Janssen Pharmaceutica, N.V. (BE) | 2012-09-05 | — | — | EP | disclosed |
| US-20120213703-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN-CILAG S.A., EDIFICIO JOHNSON & JOHNSON (ES) | 2012-08-23 | — | — | US | disclosed |
| WO-2011051324-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120213703-A1 | RADIOLABELLED PDE10 LIGANDS | PDE9A, PDE10A, PDE7A | PDE10A 2/4885PDE4B 7/4885PDE4A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.